Company: Sun Pharmaceutical Industries Ltd. Category: Company News

The interim analysis revealed that over 71% of patients treated with ILUMYA experienced a 20% improvement in joint and skin symptoms (ACR20), meeting the primary endpoint of the study.
June 14, 2019, 12:53 p.m.

Caught up in a corporate governance controversy, an insider view shows Sun trod ethical grey zones since the 1990s
May 29, 2019, 10:36 p.m.

Shares of Sun Pharmaceutical Industries closed at Rs 422.85 apiece on the BSE, up 2.41 per cent
May 29, 2019, 7:22 p.m.

Sales in the US were $443 million for the quarter, a 20 per cent increase over the same period last year, and accounted for 44 per cent of total sales
May 29, 2019, 1:14 a.m.

A ₹1,085 crore one-time charge following a governance scandal hit profit.Sudhir Valia, brother-in law of founder Dilip Shanghvi, will become a non-executive director from whole-time director
May 29, 2019, 1:03 a.m.

Drugmaker Sun Pharmaceutical Industries said that its income from operations took a one-time impact of about ₹1,085 crore due to the change of its dis
May 28, 2019, 9:19 p.m.

The company had posted a net profit of Rs 1,342.50 crore for the corresponding period of the previous fiscal
May 28, 2019, 8:17 p.m.

However, the consolidated total revenue from operations rose 3% to ₹7,164 crore.Company's board recommends dividend of ₹2.75 per share
May 28, 2019, 6:16 p.m.

After a 4-yr decline that erased 65% from the value of Sun, Shanghvi is preparing to bounce back
May 23, 2019, 12:25 a.m.

44 states have alleged the drugmakers of price fixing
May 14, 2019, 1:35 a.m.